Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion
Authors' conclusion
During episodes of hyperglycaemia commonly experienced in people with type 1 diabetes, URLi provided a faster recovery versus Humalog from a missed mealtime bolus or during basal insulin suspension. URLi shows significant acceleration of insulin absorption versus Humalog when boluses are administered by subcutaneous infusion or injection.
Study context
- Population
- Adults with T1D on CSII, with hyperglycaemia (plasma glucose (PG) >240 mg/dl) induced by a missed mealtime bolus (day 1) and by suspension of basal insulin (day 2)crossover, two periods
- Participants
- 32 adults
- Comparison
- Ultra rapid lispro (URLi) vs Humalog correction bolus
- Primary endpoint
- Time to hyperglycaemia recovery (PG = 140 mg/dl) after correction bolus
Methodological detailsdouble-blind, crossover
- Double-blind
- Crossover
Primary result
As reported in the abstract
Time to hyperglycaemia recovery
Difference
−23 min
P = 0.1
Missed mealtime bolus; faster recovery with URLi, not significant
Difference
−16 min
P < 0.01
Basal suspension; faster recovery with URLi
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| Maximum PGURLi vs Humalog · Missed mealtime bolus | difference −13 mg/dl | P = 0.02 |
| Maximum PGURLi vs Humalog · Basal suspension | difference −6 mg/dl | P = 0.02 |
| Rate of PG declineURLi vs Humalog | difference 23 mg/dl/h | P = 0.07 |
| Rate of PG declineURLi vs Humalog · Basal suspension; faster decline with URLi | difference 24 mg/dl/h | P < 0.001 |
- Rate of PG decline: Missed mealtime bolus; numerically more rapid decline with URLi
Insulin lispro absorption after correction bolus (early 50% tmax, AUC0-15min)
- Early 50% tmax reduced with URLi vs Humalog, day 1 (infusion) or day 2 (injection), respectively
- 6 or 12 min
- AUC0-15min increased with URLi vs Humalog, day 1 (infusion) or day 2 (injection), respectively
- 2.5- or 4.3-fold
- P value (all)
- P < 0.001
Original publication
Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion. Diabetes Obes Metab. Published 9 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →